17 Nov , 2026 By : Shambhavi Mishra
? Quick Take: Recent price cuts on anti-cancer drugs offer relief, but the real bottleneck is now availability. Patients in smaller cities may still pay more due to distance and distribution gaps.
The headline number is good. Prices on key anti-cancer drugs have fallen. But for millions of patients outside metro hubs, the invoice is not the only cost. The new reality is travel. If a medicine is cheaper but unavailable locally, the savings vanish under the weight of logistics and long-distance care.
Manufacturers and regulators have pushed for lower list prices. The intent is clear: reduce the financial burden on families fighting terminal illnesses. Yet, the supply chain in India’s smaller towns is fragile. Many onco-drugs require strict cold-chain management. If a local hospital lacks inventory, patients must travel to tier-1 cities for treatment.
This creates a hidden cost. A drug priced at 10,000 rupees might effectively cost 30,000 rupees when you factor in three days of travel, accommodation, and lost wages. For small-city patients, accessibility is the true price. The market is responding, but the distribution network is lagging behind the regulatory pace.
Source Attribution: Originally reported by ndtv-top (https://www.ndtv.com/business-news/anti-cancer-drug-medicine-prices-fall-small-city-patients-struggle-for-access-12306075).
Disclaimer: The financial, market, and corporate developments published above are reported for informational and educational purposes only. GrowMudra does not provide investment advice or stock recommendations. Readers are strongly advised to consult a SEBI-registered financial advisor before making investment decisions.
0 Comment